Efficacy and safety of recombinant human erythropoietin (Hema-Plus®) for management of anemia in Thai patients on peritoneal dialysis

Table 6 Adverse events (n = 37)

Adverse events	No. of patients (%)	No. of events
Total	18 (48.65)	39
Blood and lymphatic disorders
Bicytopenia1	1 (2.70)	1
Gastrointestinal disorders
Diarrhea	1 (2.70)	1
Nausea	1 (2.70)	1
Infections and infestations
Exit site infection/inflammation	6 (16.22)	6
Pneumonia1	2 (5.40)	2
Eosinophilic peritonitis	2 (5.40)	2
Injury, poisoning and procedural complications
Closed fractures of femur1	1 (2.70)	1
Accidental tear small bowel1	1 (2.70)	1
Investigations
Hyperkalemia	1 (2.70)	1
Hypokalemia	1 (2.70)	1
Hyperphosphatemia	1 (2.70)	1
Metabolism and nutrition disorders
Hypoglycemia	2 (5.40)	2
Musculoskeletal and connective tissue disorders
Acute arthritis	1 (2.70)	1
Nervous system disorders
Headache	1 (2.70)	1
Dizziness	1 (2.70)	1
Renal and urinary disorders
Volume overload1,2	1 (2.70)	1
Respiratory, thoracic and mediastinal disorders
Chest discomfort	1 (2.70)	1
Bronchospasm	1 (2.70)	1
Pleural effusion1	1 (2.70)	1
Skin and subcutaneous tissue disorders
Edema	4 (10.81)	4
Paleness	1 (2.70)	2
Cellulitis	1 (2.70)	1
Itching from dry skin	1 (2.70)	1
Surgical and medical procedures
Catheter malfunction/ malposition3	2 (5.40)	2
Vascular disorder
Hypertensive urgency1,4	2 (5.40)	2

¹Serious adverse event.

²Severe adverse event.

³Only one out of two events were serious adverse event.

⁴The causality was deemed as probable.